New Technology– category –
-
Converging 3D Bioprinting and Organoids: A Novel Approach Revolutionizing Disease Modeling and Regenerative Medicine
Oxford Academic (Regenerative Biomaterials) Global Overview The convergence of 3D bioprinting and organoid technology presents a new paradigm poised to revolutionize disease modeling, drug screening, and regenerative medicine. 3D bioprin... -
Understanding Regenerative Medicine: Distinguishing PMDA-Approved Treatments from Research in Japan
GINZA YR CLINIC Japan Overview Regenerative medicine, encompassing cell therapies, stem cell research, and tissue engineering, aims to restore damaged tissues and organs. In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) is... -
Allogene’s Off-the-Shelf CAR T Cema-Cel Secures FDA RMAT and Fast Track for High-Risk LBCL First-Line Consolidation
OncLive USA Overview Allogene Therapeutics' off-the-shelf anti-CD19 CAR T-cell therapy, cemacabtagene ansegedleucel (cema-cel), received FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for first-line consoli... -
Allogene’s Off-the-Shelf CAR T, Cema-Cel, Earns FDA RMAT and Fast Track for High-Risk LBCL First-Line Consolidation
Allogene Therapeutics, Inc. USA Overview Allogene Therapeutics has secured FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for its investigational allogeneic CAR T-cell therapy, cemacabtagene ansegedleucel (... -
iPSC-Derived Cell Therapy Pipeline Expands: Hopstem Leads Chinese Market with Neurological and Immunological Disease Applications
BioInformant USA Overview The iPSC-derived cell therapy pipeline is rapidly expanding from disease modeling to clinical applications across cardiovascular, neurological, metabolic, ocular, and oncological diseases. Hopstem Biotechnology ... -
FDA Clarifies Regenerative Medicine Regulations: Strategic Use of RMAT Designation and HCT/P Classification to Accelerate Development
Global MedTech Expert USA Overview The U.S. FDA has detailed its Regenerative Medicine Advanced Therapy (RMAT) designation, offering a fast-track development framework for cell and gene therapies targeting serious or life-threatening dis... -
AI Industry Unpacked: July 25, 2026 – NVIDIA’s Blackwell Ultra, Microsoft’s Agentic AI, and EU Regulatory Milestones
AI Industry Daily International Overview On July 25, 2026, the AI industry witnessed pivotal developments, including NVIDIA's detailed release on its next-generation 'Blackwell Ultra' AI chip, Microsoft's advancements in Agentic AI, and ... -
Databricks Announces AI Strategy in Healthcare, Accelerating Therapy Development Based on Real-World Data
Databricks Blog USA Overview Databricks has announced its AI strategy for the healthcare and life sciences sectors, aiming to transform therapy development and patient care through the fusion of real-world data (RWD) and AI. Its Lakehous... -
BFL.ai Unveils Flux-3: Accelerating Enterprise AI with Advanced LLM and Agentic Framework
BFL.ai Blog International Overview BFL.ai has announced Flux-3, an innovative large language model (LLM) and Agentic AI framework designed to accelerate complex AI application development and deployment for enterprises. This solution fea... -
DAC 2026 Highlights ‘True Challenges of AI Chip Creation’: Debating Design Complexity and Soaring Costs
EE Times USA Overview At the 2026 Design Automation Conference (DAC), a session on 'The True Challenges of AI Chip Creation' emphasized the extreme complexity and escalating costs of the design and manufacturing processes. AI chips face ...
